Recent Finacing
Recent Raise
Imago BioSciences is a clinical-stage biopharmaceutical company developing orally available LSD1 (KDM1A) inhibitors, including bomedemstat (IMG-7289), for myelofibrosis, essential thrombocythemia, and other myeloid malignancies.
